Veracyte Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Veracyte has an operating margin of 3.6%, meaning the company retains $4 of operating profit per $100 of revenue. This below-average margin results in a low score of 18/100, suggesting thin profitability after operating expenses. This is up from -23.8% the prior year.
Veracyte's revenue surged 23.5% year-over-year to $445.8M, reflecting rapid business expansion. This strong growth earns a score of 96/100.
Veracyte carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.73, Veracyte holds $4.73 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Veracyte converts 14.3% of revenue into free cash flow ($63.8M). This strong cash generation earns a score of 72/100.
Veracyte generates a 2.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 8/100.
Veracyte scores 13.85, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.8B) relative to total liabilities ($124.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Veracyte passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Veracyte generates $3.11 in operating cash flow ($75.1M OCF vs $24.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
This page shows Veracyte (VCYT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Veracyte generated $445.8M in revenue in fiscal year 2024. This represents an increase of 23.5% from the prior year.
Veracyte's EBITDA was $39.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 167.6% from the prior year.
Veracyte generated $63.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 86.2% from the prior year.
Veracyte reported $24.1M in net income in fiscal year 2024. This represents an increase of 132.4% from the prior year.
Veracyte earned $0.31 per diluted share (EPS) in fiscal year 2024. This represents an increase of 130.4% from the prior year.
Veracyte held $239.1M in cash against $0 in long-term debt as of fiscal year 2024.
Veracyte had 78M shares outstanding in fiscal year 2024. This represents an increase of 6.2% from the prior year.
Veracyte's gross margin was 66.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the prior year.
Veracyte's operating margin was 3.6% in fiscal year 2024, reflecting core business profitability. This is up 27.4 percentage points from the prior year.
Veracyte's net profit margin was 5.4% in fiscal year 2024, showing the share of revenue converted to profit. This is up 26.0 percentage points from the prior year.
Veracyte's ROE was 2.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Veracyte invested $69.3M in research and development in fiscal year 2024. This represents an increase of 20.9% from the prior year.
Veracyte invested $11.3M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 13.3% from the prior year.
VCYT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $131.9M+1.3% | $130.2M+13.7% | $114.5M-3.5% | $118.6M+3.7% | $114.4M+18.2% | $96.8M-1.4% | $98.2M+9.0% | $90.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $91.3M+1.7% | $89.8M+12.9% | $79.5M+1.0% | $78.8M+1.1% | $77.9M+24.7% | $62.5M | N/A | $57.7M |
| R&D Expenses | $16.0M-1.7% | $16.3M-8.2% | $17.7M-8.1% | $19.3M+17.2% | $16.5M+3.1% | $16.0M-14.5% | $18.7M+40.2% | $13.3M |
| SG&A Expenses | $27.3M-15.6% | $32.3M-4.4% | $33.8M+25.6% | $26.9M-15.2% | $31.7M+21.1% | $26.2M+10.1% | $23.8M+45.7% | $16.3M |
| Operating Income | $22.9M+535.6% | -$5.3M-281.4% | $2.9M-30.4% | $4.2M-9.4% | $4.6M+198.9% | -$4.7M+86.9% | -$35.5M-11.9% | -$31.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$248K-111.1% | $2.2M+485.3% | $381K+122.8% | -$1.7M-202.6% | $1.6M+3797.7% | -$44K+98.0% | -$2.2M-1314.9% | -$154K |
| Net Income | $19.1M+2052.8% | -$980K-113.9% | $7.0M+37.8% | $5.1M-10.8% | $5.7M+407.6% | -$1.9M+93.4% | -$28.3M+4.5% | -$29.6M |
| EPS (Diluted) | $0.24+2500.0% | $-0.01-111.1% | $0.09+28.6% | $0.070.0% | $0.07+450.0% | $-0.02+94.7% | $-0.38+7.3% | $-0.41 |
VCYT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+1.8% | $1.3B+2.2% | $1.3B+1.2% | $1.3B+5.3% | $1.2B+2.9% | $1.2B+7.6% | $1.1B-0.9% | $1.1B |
| Current Assets | $449.2M+8.3% | $414.7M+8.2% | $383.2M+2.9% | $372.3M+15.9% | $321.1M+10.6% | $290.4M+1.7% | $285.6M+5.3% | $271.2M |
| Cash & Equivalents | $315.6M+43.8% | $219.5M+17.9% | $186.1M-22.2% | $239.1M+1.3% | $235.9M+12.8% | $209.2M-3.4% | $216.5M+6.9% | $202.5M |
| Inventory | $20.3M-18.8% | $25.0M+3.2% | $24.3M+11.5% | $21.8M+12.9% | $19.3M+5.1% | $18.3M+13.6% | $16.1M+1.5% | $15.9M |
| Accounts Receivable | $47.8M-5.9% | $50.8M-5.5% | $53.8M+15.6% | $46.5M-7.5% | $50.3M+7.8% | $46.7M+15.6% | $40.4M+2.8% | $39.3M |
| Goodwill | $767.2M-0.8% | $773.3M+2.5% | $754.3M+1.1% | $745.8M-0.8% | $752.1M-0.2% | $753.9M+7.2% | $703.0M+1.4% | $693.2M |
| Total Liabilities | $110.1M-10.5% | $123.0M+2.1% | $120.5M-2.9% | $124.1M+21.9% | $101.8M+25.0% | $81.4M+15.0% | $70.8M-0.1% | $70.9M |
| Current Liabilities | $72.2M-5.6% | $76.4M+1.7% | $75.1M-4.5% | $78.6M+8.7% | $72.3M+24.6% | $58.1M-5.2% | $61.2M+7.0% | $57.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.3B+3.0% | $1.2B+2.2% | $1.2B+1.6% | $1.2B+3.8% | $1.1B+1.2% | $1.1B+7.1% | $1.0B-0.9% | $1.1B |
| Retained Earnings | -$418.8M+4.4% | -$437.9M-0.2% | -$436.9M+1.6% | -$444.0M+4.4% | -$464.3M+1.2% | -$470.0M-0.4% | -$468.1M-6.4% | -$439.8M |
VCYT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $44.8M+33.2% | $33.6M+526.7% | $5.4M-78.1% | $24.5M-17.1% | $29.6M+429.9% | -$9.0M-157.7% | $15.6M+9.7% | $14.2M |
| Capital Expenditures | $2.8M+117.1% | $1.3M-29.3% | $1.8M-56.1% | $4.1M+49.5% | $2.8M+29.8% | $2.1M-14.5% | $2.5M-10.9% | $2.8M |
| Free Cash Flow | $42.0M+29.8% | $32.3M+812.2% | $3.5M-82.6% | $20.4M-24.0% | $26.8M+341.5% | -$11.1M-185.0% | $13.1M+14.8% | $11.4M |
| Investing Cash Flow | $48.3M+21646.0% | -$224K+99.6% | -$51.8M+4.3% | -$54.1M-1854.5% | -$2.8M-196.2% | $2.9M+215.3% | -$2.5M+10.9% | -$2.8M |
| Financing Cash Flow | $3.0M+626.0% | -$566K+91.3% | -$6.5M-43.8% | -$4.5M-40900.0% | -$11K+98.7% | -$864K-234.0% | $645K+486.4% | $110K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VCYT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.2%+0.3pp | 69.0%-0.5pp | 69.5%+3.1pp | 66.4%-1.7pp | 68.1%+3.6pp | 64.5% | N/A | 64.0% |
| Operating Margin | 17.4%+21.4pp | -4.0%-6.6pp | 2.5%-1.0pp | 3.5%-0.5pp | 4.0%+8.8pp | -4.8%+31.4pp | -36.2%-0.9pp | -35.2% |
| Net Margin | 14.5%+15.3pp | -0.8%-6.9pp | 6.2%+1.9pp | 4.3%-0.7pp | 5.0%+6.9pp | -1.9%+26.9pp | -28.8%+4.1pp | -32.9% |
| Return on Equity | 1.5% | N/A | 0.6%+0.2pp | 0.4%-0.1pp | 0.5% | N/A | N/A | N/A |
| Return on Assets | 1.4%+1.5pp | -0.1%-0.6pp | 0.5%+0.2pp | 0.4%-0.1pp | 0.5%+0.6pp | -0.2%+2.4pp | -2.5%+0.1pp | -2.6% |
| Current Ratio | 6.23+0.8 | 5.43+0.3 | 5.10+0.4 | 4.73+0.3 | 4.44-0.6 | 5.00+0.3 | 4.66-0.1 | 4.74 |
| Debt-to-Equity | 0.09-0.0 | 0.100.0 | 0.100.0 | 0.11+0.0 | 0.09+0.0 | 0.070.0 | 0.070.0 | 0.07 |
| FCF Margin | 31.8%+7.0pp | 24.8%+21.7pp | 3.1%-14.1pp | 17.2%-6.3pp | 23.4%+34.9pp | -11.5%-24.8pp | 13.3%+0.7pp | 12.6% |
Similar Companies
Frequently Asked Questions
What is Veracyte's annual revenue?
Veracyte (VCYT) reported $445.8M in total revenue for fiscal year 2024. This represents a 23.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Veracyte's revenue growing?
Veracyte (VCYT) revenue grew by 23.5% year-over-year, from $361.1M to $445.8M in fiscal year 2024.
Is Veracyte profitable?
Yes, Veracyte (VCYT) reported a net income of $24.1M in fiscal year 2024, with a net profit margin of 5.4%.
What is Veracyte's earnings per share (EPS)?
Veracyte (VCYT) reported diluted earnings per share of $0.31 for fiscal year 2024. This represents a 130.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Veracyte's EBITDA?
Veracyte (VCYT) had EBITDA of $39.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Veracyte's gross margin?
Veracyte (VCYT) had a gross margin of 66.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Veracyte's operating margin?
Veracyte (VCYT) had an operating margin of 3.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Veracyte's net profit margin?
Veracyte (VCYT) had a net profit margin of 5.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Veracyte's return on equity (ROE)?
Veracyte (VCYT) has a return on equity of 2.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Veracyte's free cash flow?
Veracyte (VCYT) generated $63.8M in free cash flow during fiscal year 2024. This represents a 86.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Veracyte's operating cash flow?
Veracyte (VCYT) generated $75.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Veracyte's total assets?
Veracyte (VCYT) had $1.3B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Veracyte's capital expenditures?
Veracyte (VCYT) invested $11.3M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Veracyte spend on research and development?
Veracyte (VCYT) invested $69.3M in research and development during fiscal year 2024.
How many shares does Veracyte have outstanding?
Veracyte (VCYT) had 78M shares outstanding as of fiscal year 2024.
What is Veracyte's current ratio?
Veracyte (VCYT) had a current ratio of 4.73 as of fiscal year 2024, which is generally considered healthy.
What is Veracyte's debt-to-equity ratio?
Veracyte (VCYT) had a debt-to-equity ratio of 0.11 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Veracyte's return on assets (ROA)?
Veracyte (VCYT) had a return on assets of 1.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Veracyte's Altman Z-Score?
Veracyte (VCYT) has an Altman Z-Score of 13.85, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Veracyte's Piotroski F-Score?
Veracyte (VCYT) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Veracyte's earnings high quality?
Veracyte (VCYT) has an earnings quality ratio of 3.11x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Veracyte?
Veracyte (VCYT) scores 66 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.